Clinical Trial Results:
A phase III, randomized, double-blind, placebo-controlled, parallel
group safety and efficacy study of BI 10773 (10 mg and 25 mg
administered orally once daily) during 52 weeks in patients with type 2
diabetes mellitus and insufficient glycemic control on MDI insulin
regimen alone or with metformin.
Summary
|
|
EudraCT number |
2010-019968-37 |
Trial protocol |
FI DE BE ES CZ BG |
Global completion date |
22 Apr 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 May 2016
|
First version publication date |
09 Apr 2015
|
Other versions |
|
Summary report(s) |
1245.49 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.